PE20040749A1 - Piperidinas espirosustituidas como antagonistas selectivos del receptor de la hormona concentradora de melanina - Google Patents

Piperidinas espirosustituidas como antagonistas selectivos del receptor de la hormona concentradora de melanina

Info

Publication number
PE20040749A1
PE20040749A1 PE2003000647A PE2003000647A PE20040749A1 PE 20040749 A1 PE20040749 A1 PE 20040749A1 PE 2003000647 A PE2003000647 A PE 2003000647A PE 2003000647 A PE2003000647 A PE 2003000647A PE 20040749 A1 PE20040749 A1 PE 20040749A1
Authority
PE
Peru
Prior art keywords
melanin
spirosustituted
piperidins
hormone receptor
cr2r3
Prior art date
Application number
PE2003000647A
Other languages
English (en)
Spanish (es)
Inventor
Duane A Burnett
Wen-Lian Wu
Martin S Domalski
Thavalakulam K Sasikumar
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20040749A1 publication Critical patent/PE20040749A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2003000647A 2002-06-27 2003-06-26 Piperidinas espirosustituidas como antagonistas selectivos del receptor de la hormona concentradora de melanina PE20040749A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39181302P 2002-06-27 2002-06-27

Publications (1)

Publication Number Publication Date
PE20040749A1 true PE20040749A1 (es) 2004-10-23

Family

ID=30000757

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000647A PE20040749A1 (es) 2002-06-27 2003-06-26 Piperidinas espirosustituidas como antagonistas selectivos del receptor de la hormona concentradora de melanina

Country Status (14)

Country Link
US (1) US7109207B2 (https=)
EP (1) EP1532147B1 (https=)
JP (1) JP4522853B2 (https=)
CN (1) CN100374440C (https=)
AR (1) AR040344A1 (https=)
AT (1) ATE334983T1 (https=)
AU (1) AU2003258957A1 (https=)
CA (1) CA2490531C (https=)
DE (1) DE60307289T2 (https=)
ES (1) ES2266861T3 (https=)
MX (1) MXPA05000185A (https=)
PE (1) PE20040749A1 (https=)
TW (1) TW200401777A (https=)
WO (1) WO2004002987A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2468015A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 2-aminoquinoline compounds
US7727998B2 (en) 2003-02-10 2010-06-01 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
ES2305735T3 (es) * 2003-02-28 2008-11-01 Schering Corporation Biariltetrahidroisoquinolin-piperidinas como antagonistas del receptor de mch selectivos, para el tratamiento de obesidad y trastornos relacionados.
CA2563164A1 (en) 2004-03-29 2005-10-06 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
US20100184648A1 (en) * 2005-03-29 2010-07-22 Akira Gomori Therapeutic agent for non-alcoholic fatty liver disease, and screening method for drug candidate compound for treatment or prevention of non-alcoholic fatty liver disease
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
US8937181B2 (en) * 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
TW200815353A (en) * 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
AU2007301126A1 (en) * 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US9963739B2 (en) 2010-05-21 2018-05-08 Hewlett-Packard Development Company, L.P. Polymerase chain reaction systems
WO2011146069A1 (en) 2010-05-21 2011-11-24 Hewlett-Packard Development Company, L.P. Fluid ejection device including recirculation system
TW201632522A (zh) * 2014-11-21 2016-09-16 伊史帝夫博士實驗室股份有限公司 針對疼痛具有多模式活性的螺-異喹啉-1,4’-哌啶化合物
CN107312056B (zh) * 2017-08-24 2019-10-25 广西师范学院 2-(3’-羟基-17’-孕甾烷基)-5-氟苯并咪唑的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
TWI279402B (en) * 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
CA2381111A1 (en) * 1999-08-26 2001-03-01 Leah M. Giupponi Npy antagonists: spiroisoquinolinone derivatives
EP1268000A4 (en) * 2000-03-23 2004-12-29 Merck & Co Inc SPIROPIPERID DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS
EP1299362A4 (en) * 2000-07-05 2004-11-03 Synaptic Pharma Corp SELECTIVE RECEPTOR ANTAGONISTS OF MELANINE CONCENTRATING HORMON-1 (MCH1) AND THEIR USE

Also Published As

Publication number Publication date
AR040344A1 (es) 2005-03-30
US7109207B2 (en) 2006-09-19
CN100374440C (zh) 2008-03-12
AU2003258957A1 (en) 2004-01-19
ES2266861T3 (es) 2007-03-01
JP4522853B2 (ja) 2010-08-11
CA2490531A1 (en) 2004-01-08
EP1532147A1 (en) 2005-05-25
WO2004002987A1 (en) 2004-01-08
CN1665812A (zh) 2005-09-07
US20040024002A1 (en) 2004-02-05
CA2490531C (en) 2011-03-22
HK1071567A1 (en) 2005-07-22
ATE334983T1 (de) 2006-08-15
DE60307289T2 (de) 2007-10-18
JP2005535641A (ja) 2005-11-24
MXPA05000185A (es) 2005-04-08
DE60307289D1 (de) 2006-09-14
TW200401777A (en) 2004-02-01
EP1532147B1 (en) 2006-08-02

Similar Documents

Publication Publication Date Title
PE20040749A1 (es) Piperidinas espirosustituidas como antagonistas selectivos del receptor de la hormona concentradora de melanina
ES2524045T3 (es) Nuevas amidas y tioamidas heteroaromáticas como plaguicidas
PE20040960A1 (es) Derivados de piperazina acilados como agonistas del receptor de melanocortina-4
ECSP056016A (es) Nuevos derivados de 2-piridinacarboxamida
WO2007075629A3 (en) Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
ECSP055615A (es) Nuevos compuestos de amida de ácido carboxílico con efecto antagónico de la hcm, medicamentos que contienen estos compuestos y procedimientos para su preparación
PE20040687A1 (es) Quinolinas sustituidas como antagonistas del receptor ccr5
PE20061353A1 (es) Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa
NO20050164L (no) Nye quinuklidin-amid-derivater
PE20051048A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasa
MY134017A (en) Mch antagonists and their use in the treatment of obesity
AR036939A1 (es) Antagonistas de la hormona de concentracion de melanina (mch) composiciones farmaceuticas, un proceso para su elaboracion y el uso de dichos compuestos, solos o en combinacion, para la elaboracion de un medicamento para el tratamiento de obesidad
NO20050749L (no) Nye alkyn-forbindelser med MCH-antagonistisk effekt og medikamenter inneholdende disse forbindelsene
TW200806629A (en) Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
NO20044826L (no) Pyrrolidinderivater
AR049652A1 (es) Sales cuaternarias antagonistas del receptor ccr2
DE602005013248D1 (de) Amidderivate von 3-phenyldihydropyrimidoä4,5-düpyrimidinonen, deren herstellung und verwendung als pharmazeutische mittel
PE20081485A1 (es) Derivados de sulfonamida
DE60318219D1 (de) PYRIMIDINDERIVATE ALS MODULATOREN DER AKTIVITuT VON CHEMOKINREZEPTOREN
PE20050231A1 (es) Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3
RU2006112847A (ru) Производные тиазолопиридина в качестве лигандов аденозинового рецептора
CY1108880T1 (el) Παραγωγα καρβοξαμιδιου ως ανταγωνιστες μουσκαρινικου υποδοχεα
PE20081876A1 (es) Aminoamidas como antagonistas de orexina
EA200801909A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
AR067412A1 (es) Moduladores de propiedades farmaceuticas de productos terapeuticos

Legal Events

Date Code Title Description
FC Refusal